HCPCS Level II code J1747 designates a 1 mg injection of spesolimab-sbzo, a monoclonal antibody administered as a parenteral biologic therapy. This national-level billing code is used to report individual billed units of the drug across outpatient infusion centers, hospital outpatient departments, and physician offices. Accurate coding of high-cost biologics like spesolimab-sbzo is important for claims processing, benefit determination, and coverage policy application.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how J1747 is used in practice, what sites of service commonly bill the code, and the implications for payer coverage and prior authorization processes.

Readers will find benchmarks and billing context for J1747 (where available), a summary of payer coverage considerations, and clinical context explaining the service type and typical settings. The report also highlights common billing modifiers and notes on administrative handling of injectable biologics. Data not available in the input will be explicitly marked as such where applicable.